Angela Demichele
University of California-San Francisco, CA·Medicine & Clinical Research
Women with early breast cancer often receive drugs before surgery, called neoadjuvant therapy, to shrink the tumor. Not every patient benefits from a given drug.
- Fields
Medicine & Clinical Research
Public Health & Epidemiology
- Topics
breast cancer
neoadjuvant therapy
I-SPY2.2
- Grants
- 1 known grant, through Jun 2028
What they work on
- Refine escalation and de-escalation decisions in the I-SPY2.2 breast cancer trial by adding circulating tumor DNA (ctDNA) and the Response Predictive Subtype scheme at key decision points, aiming to raise pathologic complete response rates.
- Improve sequential randomization so that poor responders move to best-in-class rescue therapies and exceptional responders avoid unnecessary treatment, building on tools from Projects 2–4.
- Develop new measures for comparing tested drugs, including changes in residual cancer burden (RCB) and combined efficacy-toxicity scores that use patient-reported outcomes.
- Evaluate how patient-reported outcomes and returning response results to patients affect patient perception, shared decision-making, and risk of adverse psychological outcomes.
More about the research
Adding more drugs to the standard regimen also brings more side effects. A key question is how to match each patient to the treatment most likely to clear her cancer, while sparing her drugs that are not working.
Why it matters
Patients with early breast cancer could benefit from more personalized treatment before surgery. Better response monitoring could move poor responders quickly to effective rescue therapies and let strong responders skip toxic drugs they do not need. The work could also help doctors and patients discuss treatment results and make care decisions together.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Hunter Underhill
University of Utah, UT·Medicine & Clinical Research
Reduce errors from next-generation sequencing so that very rare tumor DNA variants can be detected in blood plasma from glioblastoma patients.
Benjamin Kozower
Washington University in St Louis, MO·Medicine & Clinical Research
Compare 3-year disease-free survival after surgery versus stereotactic body radiation therapy (SBRT) in patients with clinical stage I non-small cell lung cancer, using propensity score–matched cohorts from a multi-center prospective study.
Melissa Mannion
University of Alabama at Birmingham, AL·Medicine & Clinical Research·Early-career
Identify the characteristics a treatment-escalation shared decision-making tool for juvenile idiopathic arthritis needs, using nominal group technique with patients, parents and providers.
The school
University of California-San Francisco: 89 labs on PI Pages, $2.1B a year on research, 164 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.